News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fosun Pharma Acquires Cancer Drug Candidate From US-based Kolltan Pharma



11/4/2016 10:58:53 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Fosun Pharma has acquired China rights to an anti-MET monoclonal antibody developed by Kolltan Pharma, a clinical stage New Haven, Connecticut biotech. In preclinical studies, KTN0216 is being tested against neuroblastoma, a form of brain cancer. Kolltan expects KTN0216 will prove to be effective against HGF-dependent and MET-amplified tumors. According to Kolltan's website, KTN0216 is about to begin IND-enabling studies. Financial details of the agreement were not disclosed.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES